The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Sunbird Bio secures partnership funding for neurological diagnostic platform
Oct 17, 2024•over 1 year ago
Contract Type
partnership
CambridgeBiotechnology
Description
Sunbird Bio has secured $14m in funding from American pharmaceutical giant Eli Lilly and the Singapore Economic Development Board (EDBI) to advance the clinical development of their blood-based diagnostic platform for neurological disorders. The investment will be used to establish a new laboratory space and initiate additional clinical studies of its diagnostic technology by early 2025.
Company Information
Company
SunBird Bio
Location
35 CAMBRIDGEPARK DR.
Cambridge, Massachusetts, United States
About
Sunbird Bio is a leader in protein-based diagnostic tests, becoming the first company to overcome the challenge of accurately detecting and differentiating the specific proteins that aggregate, and therefore signal the presence of Alzheimer’s disease, with a simple blood draw. We are addressing the tremendous, growing need for more reliable and sensitive diagnostic tests to accelerate drug development and enhance patient care.
CambridgeBiotechnology